Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Geron

- PMLiVE

J&J’s Erleada first US drug for non-metastatic prostate cancer

Drug approved by the FDA on the back of data from the SPARTAN study

- PMLiVE

J&J extends its JLABS incubator scheme to Europe

The Belgian site will accommodate up to 30 life science start-ups

- PMLiVE

AZ gets early FDA green light for Imbruvica challenger

Sets up a marketing battle with Johnson/AbbVie

- PMLiVE

J&J seeks US OK to add CV claim to Invokana label

If approved the treatment could better compete with rivals Jardiance and Victoza

- PMLiVE

Biosimilars eat into J&J’s Remicade sales

But its IL-23 inhibitor 'signals better times ahead'

Actelion HQ Switzerland

Actelion reports late-stage trial failure as J&J talks continue

MAESTRO trial results disappointing but unlikely to lead to a breakdown in talks

- PMLiVE

J&J back in frame to buy Actelion after Sanofi talks break down

Parties now in exclusive negotiations about a possible deal

- PMLiVE

J&J is to appeal Remicade patent ruling in US

As Pfizer is poised to bring biosimilar version to market

- PMLiVE

J&J therapy for suicidal depressives ‘a breakthrough’, says FDA

Status granted to esketamine after phase II PeRSERVERe trial

- PMLiVE

Universal vaccine could end ‘flu season’ scramble

Researchers a step closer in creating lifelong jab

- PMLiVE

J&J chief predicts 10 new pharma filings by 2017

 Company has launched 14 new products since 2009

- PMLiVE

J&J names head of marketing for Northern Europe

Yana Ignatova joins from Procter & Gamble

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links